Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) [sabarubicin] in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every 3 Weeks

Trial Profile

Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) [sabarubicin] in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every 3 Weeks

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2012

At a glance

  • Drugs Sabarubicin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top